Phenylephrine on USP-NF
This article was originally published in The Tan Sheet
Executive Summary
Bayer's Consumer Care division is "looking forward to" the inclusion of phenylephrine bitartrate in FDA's monograph for OTC Nasal Decongestant Products following the ingredient's Aug. 1 addition to the U.S. Pharmacopeia's National Formulary, Bayer says in a recent letter to FDA. The monograph amendment would apply to phenylephrine's use in effervescent tablets when used in combination with chlorpheniramine maleate and aspirin, and was proposed by FDA in November 2004 (1"The Tan Sheet" Nov. 8, 2004, p. 11). Phenylephrine's inclusion in the USP-NF is a prerequisite of its addition to the monograph. Bayer, which markets the Alka-Seltzer line of effervescent cough/cold products, submitted comments supporting the monograph amendment in February (2"The Tan Sheet" Feb. 14, 2005, p. 7)...
You may also be interested in...
Decongestant Monograph Definition Expansion Requested By Bayer
FDA should revise its definition of effervescent cold products containing phenylephrine bitartrate (PEB) to make it more flexible, Bayer states in recent comments to FDA
Bayer Bubbles Over Proposed Cough/Cold Monograph Amendment
FDA is proposing to amend the over-the-counter nasal decongestant drugs monograph to include phenylephrine bitartrate (PEB) in effervescent tablets, according to an announcement published in the Federal Register Nov. 2
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.